Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Dexamethasone 3.3 mg/ml Solution for Injection (vial)

Active Ingredient:
dexamethasone sodium phosphate
Hospira UK Ltd See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 29 Feb 2024
1. Name of the medicinal product

Dexamethasone 3.3 mg/ml Solution for Injection

2. Qualitative and quantitative composition

Each ml of solution contains 3.3 mg dexamethasone (as sodium phosphate) which is equivalent to 4 mg dexamethasone phosphate or 4.3 mg dexamethasone sodium phosphate.

Each 2 ml contains 6.6 mg dexamethasone (as sodium phosphate) which is equivalent to 8 mg dexamethasone phosphate or 8.6 mg dexamethasone sodium phosphate.

Excipients with known effect:

Each millilitre (ml) of solution contains 0.07 milligrams (mg) of sodium sulfite (E 221). Each vial of 2 ml of solution contains 0.14 mg of sodium sulfite (E 221).

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Solution for injection

A clear, colourless solution free from particulate matter

4. Clinical particulars
4.1 Therapeutic indications

Dexamethasone Solution for Injection is indicated in acute conditions in which oral glucocorticoid therapy is not feasible such as:

Shock: of haemorrhagic, traumatic, surgical or septic origin; cerebral oedema associated with cerebral neoplasm; inflammatory diseases of joints and soft tissue such as rheumatoid arthritis.

Short term management of acute self-limited allergic conditions such as angioneurotic oedema or acute exacerbations of chronic allergic disorders such as bronchial asthma or serum sickness.

High doses of dexamethasone are intended for the adjunctive treatment of shock where massive doses of corticosteroids are needed. There is a lack of evidence that use of corticosteroids in septic shock affects mortality in the long term. Use must be accompanied by the appropriate concomitant systemic antibiotic treatment and supportive measures which the patient's condition may require.

4.2 Posology and method of administration

Not for intrathecal use – contains sulfites.

N.B. All doses are expressed as mg dexamethasone base.

The lowest effective dose should be used for the minimum period and this should be reviewed frequently to appropriately titrate the dose against disease activity (See section 4.4).

Dexamethasone 3.3 mg/ml Solution for Injection may be administered by intramuscular, intraarticular or direct intravenous injection, intravenous infusion or soft tissue infiltration.

Intravenous and Intramuscular Administration: IM or IV dosage of dexamethasone is variable, depending on the condition being treated. It usually ranges from 0.4 to 20 mg (0.1 to 6 ml) daily. The duration of therapy is dependent on the clinical response of the patient and as soon as improvement is indicated, the dosage should be adjusted to the minimum required to maintain the desired clinical response. Withdrawal of the drug on completion of therapy should be gradual.

Shock: A single IV injection of 1.67 to 5 mg/kg (0.5 to 1.5 ml/kg) bodyweight which may be repeated in 2-6 hours if shock persists. High-dose therapy should be continued only until the patient's condition has stabilised and usually for no longer than 48-72 hours. This bolus injection can then be followed by continuous IV infusion of 2.5 mg/kg (0.75 ml/kg) bodyweight per 24 hours. Dexamethasone 3.3 mg/ml Solution for Injection can be diluted with Sodium Chloride Injection BP or Glucose Injection BP.

Cerebral oedema associated with neoplasm: An initial dose of 8.3 mg (2.5 ml) IV followed by 3.3 mg (1.0 ml) IM every 6 hours until the symptoms of oedema subside (usually after 12 to 24 hours). After 2 to 4 days the dosage should be reduced and gradually stopped over a period of 5 to 7 days. In patients with recurrent or inoperable neoplasms, maintenance therapy may be effective at doses of 1.7 mg (0.5 ml) IM or IV 2-3 times daily.

Life-Threatening Cerebral Oedema:

High Dose Schedule (all doses are expressed as mg dexamethasone base):


Children > 35 kg

Children < 35 kg

Initial dose

41.6 mg (12.5 ml) IV

20.8 mg IV (6.25 ml)

16.7 mg (5.0 ml) IV

1st day

6.6 mg (2.0 ml) IV every 2 hrs

3.3 mg (1.0 ml) IV every 2 hrs

3.3 mg (1.0 ml) IV every 3 hrs

2nd day

6.6 mg (2.0 ml) IV every 2 hrs

3.3 mg (1.0 ml) IV every 2 hrs

3.3 mg (1.0 ml) IV every 3 hrs

3rd day

6.6 mg (2.0 ml) IV every 2 hrs

3.3 mg (1.0 ml) IV every 2 hrs

3.3 mg (1.0 ml) IV every 3 hrs

4th day

3.3 mg (1.0 ml) IV every 2 hrs

3.3 mg (1.0 ml) IV every 4 hrs

3.3 mg (1.0 ml) IV every 6 hrs

5th – 8th day

3.3 mg (1.0 ml) IV every 4 hrs

3.3 mg (1.0 ml) IV every 6 hrs

1.7 mg (0.5 ml) IV every 6 hrs

After 8 days

Decrease by daily reduction of 3.3 mg (1.0 ml)

Decrease by daily reduction of 1.7 mg (0.5 ml)

Decrease by daily reduction of 0.8 mg (0.25 ml)

Note: The intravenous and intramuscular routes of administration of dexamethasone should only be used where acute illness or life-threatening situations exist. Oral therapy should be substituted as soon as possible.

Intraarticular and Soft Tissue Injections

Dosage varies with the degree of inflammation and the size and location of the affected area. Injections may be repeated from once every 3-5 days (e.g. for bursae) to once every 2-3 weeks (for joints).

Site of Injection

1. Large Joint

2. Small Joints

3. Bursae

4. Tendon Sheaths

5. Soft Tissue Infiltration

6. Ganglia


1.7 mg to 3.3 mg (0.5 ml to 1.0 ml)

667 micrograms to 0.8 mg (0.2 ml to 0.25 ml)

1.6 mg to 2.5 mg (0.5 ml to 0.75 ml)

333 micrograms to 0.8 mg (0.1 ml to 0.25 ml)

1.7 mg to 5 mg (0.5 ml to 1.5 ml)

0.8 mg to 1.7 mg (0.25 ml to 0.5 ml)

Paediatric population

Dosage requirements are variable and may have to be changed according to individual need. Usually 167 micrograms/kg to 333 micrograms/kg (0.05 ml/kg to 0.1 ml/kg) of body weight daily.

Corticosteroids cause growth retardation in infancy, childhood and adolescence, which may be irreversible. Treatment should be limited to the minimum dosage for the shortest possible time. In order to minimise suppression of the hypothalamic-pituitary-adrenal axis and growth retardation, treatment should be limited, where possible, to a single dose on alternate days.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully monitored.


Treatment of elderly patients, particularly long-term, should be planned, bearing in mind the more serious consequences in old age. Such effects include osteoporosis, hypertension, hypokalaemia, diabetes, susceptibility to infection, thinning and fragility of the skin. Close clinical supervision is required to avoid life-threatening reactions.

4.3 Contraindications

Unless considered to be life-saving systemic administration of corticosteroids are generally contraindicated in patients with systemic infections, (unless specific anti-infective therapy is employed). Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Local injection of a corticosteroid is contraindicated in:

• bacteraemia

• systemic fungal infections

• unstable joints

• infection at the injection site e.g. septic arthritis resulting from gonorrhea or tuberculosis

Administration of dexamethasone is contraindicated in patients with a known hypersensitivity to sulfites.

4.4 Special warnings and precautions for use


A Patient Information Leaflet should be supplied with this product.

In post marketing experience tumour lysis syndrome (TLS) has been reported in patients with haematological malignancies following the use of dexamethasone alone or in combination with other chemotherapeutic agents. Patients at high risk of TLS, such as patients with high proliferative rate, high tumour burden and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precaution taken.

Patients and/or carers should be warned that potentially severe psychiatric adverse reactions may occur with systemic steroids (see section 4.8). Symptoms typically emerge within a few days or weeks of starting the treatment. Risks may be higher with high doses/systemic exposure (see also section 4.5 pharmacokinetic interactions that can increase the risk of side effects), although dose levels do not allow prediction of the onset, type, severity or duration of reactions. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary. Patients/carers should be encouraged to seek medical advice if worrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected. Patients/carers should also be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids, although such interactions have been reported infrequently.

Particular care is required when considering the use of systemic corticosteroids in patients with existing or previous history of severe affective disorders in themselves or in their first degree relatives. These would include depressive or manic-depressive illness and previous steroid psychosis.

The lowest effective dose of corticosteroid should be used to control the condition under treatment for the minimum period. Frequent patient review is required to appropriately titrate the dose against disease activity (See dosage section). When dose reduction is possible, it should occur gradually. Too rapid a reduction of dexamethasone dosage following prolonged treatment can lead to acute adrenal insufficiency, hypotension and death.

A 'withdrawal syndrome' may also occur including fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules and loss of weight.

Adrenal suppression: Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must, therefore, be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment. During prolonged therapy any intercurrent illness, trauma or surgical procedure will require a temporary increase in dosage; if corticosteroids have been stopped following prolonged therapy they may need to be temporarily re-introduced.

Patients should carry 'steroid treatment' cards which give clear guidance on the precautions to be taken to minimise risk and which provide details of prescriber, drug, dosage and the duration of treatment.

There is a lack of evidence to support the prolonged use of corticosteroids in septic shock. Although they may be of value in the early treatment, the overall survival may not be influenced.

Severe anaphylactoid reactions have occurred after administration of parenteral corticosteroids. Glottis oedema, urticaria and bronchospasm, have occasionally occurred particularly in patients with history of allergy. Appropriate precautions should be taken prior to administration. If such an anaphylactoid reaction occurs, the following measures are recommended: immediate slow intravenous injection of adrenaline, intravenous administration of aminophylline, and artificial respiration if necessary.

Corticosteroids should not be used for the management of head injury or stroke because it is unlikely to be of any benefit and may even be harmful.

The results of a randomized, placebo-controlled study suggest an increase in mortality if methylprednisolone therapy starts more than two weeks after the onset of Acute Respiratory Distress Syndrome (ARDS). Therefore, treatment of ARDS with corticosteroids should be initiated within the first two weeks of onset of ARDS.

The slower rate of absorption after intramuscular injection should be noted.

Intraarticular corticosteroids are associated with a substantially increased risk of an inflammatory response in the joint, particularly a bacterial infection introduced with the injection. Great care is required and all intraarticular corticosteroid injections should be undertaken in an aseptic environment. Charcot like arthropathies have been reported particularly after repeated injections.

Prior to intraarticular injection the joint fluid should be examined to exclude a septic process. A marked increase in pain, accompanied by local swelling, further restriction of joint motion, fever and malaise are suggestive of septic arthritis. If this complication occurs and sepsis is confirmed, appropriate antimicrobial therapy should be commenced.

Patients should be impressed strongly with the importance of not overusing joints in which symptomatic benefit has been obtained, but the inflammatory process remains active.

Appropriate antimicrobial therapy should accompany glucocorticoid therapy when necessary e.g. in tuberculosis and viral and fungal infections of the eye.

Suppression of the inflammatory response and the immune function increases the susceptibility to infections and their severity. The clinical presentation may be atypical and serious infections, such as septicaemia and tuberculosis, may be masked and may reach an advanced stage before being recognised.

Chickenpox is of particular concern since this normally minor illness may be fatal in immunosuppressed patients. Patients (or parents of children) without a definite history of chickenpox should be advised to avoid close personal contact with chickenpox or herpes zoster and if exposed they should seek urgent medical attention. Passive immunisation with varicella zoster immunoglobulin (VZIG) is needed by exposed non-immune patients who are receiving systemic dexamethasone or who have received it during the previous 3 months; this should be given within 10 days of exposure to chickenpox. If a diagnosis of chickenpox is confirmed, the illness warrants specialist care and urgent treatment. Dexamethasone should not be stopped and the dose may need to be increased.

Patients should be advised to take particular care to avoid exposure to measles and to seek immediate medical advice if exposure occurs; prophylaxis with intramuscular normal immunoglobin may be needed.

Live vaccines should not be given to individuals with impaired immune responsiveness. The antibody response to other vaccines may be diminished.

False negative results may occur with the nitroblue tetrazolium test for bacterial infection.

Extreme caution should be exercised in the treatment of patients with the following conditions and frequent patient monitoring is necessary:

• Liver failure, chronic renal failure, renal insufficiency, congestive heart failure, hypertension, epilepsy, migraine and incomplete statural growth since glucocorticoids on prolonged administration may accelerate epiphyseal closure.

• Osteoporosis, since corticosteroids increase calcium excretion. Post-menopausal women are at particular risk.

• Latent tuberculosis, as corticosteroids can cause reactivation.

• Hypothyroidism or cirrhosis, because such patients often show an exaggerated response to corticosteroids.

• Latent amoebiasis, as corticosteroids can cause reactivation. Prior to treatment, amoebiasis should be ruled out in any patient with unexplained diarrhoea or who has recently spent time in the tropics.

• Ocular herpes simplex, because corticosteroids may cause corneal perforation.

Corticosteroids should also be used with caution in patients with diabetes mellitus (or a family history of diabetes), affective disorders (especially previous steroid psychosis), glaucoma (or a family history of glaucoma), peptic ulceration or previous corticosteroid-induced myopathy.

In the treatment of conditions such as tendinitis or tenosynovitis care should be taken to inject into the space between the tendon sheath and the tendon as cases of ruptured tendon have been reported.

Visual disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Dexamethasone has been used 'off– label' to treat and prevent chronic lung disease in preterm infants. Clinical trials have shown a short term benefit in reducing ventilator dependence but no long term benefit in reducing time to discharge, the incidence of chronic lung disease or mortality. Available evidence suggests long-term neurodevelopmental adverse events after early treatment (< 96 hours) of premature infants with chronic lung disease at starting doses of 0.25mg/hg twice daily. Recent trials have suggested an association between the use of dexamethasone in preterm infants and the development of cerebral palsy. In view of this possible safety concern, an assessment of the risk: benefit should be made on an individual patient basis.

Pheochromocytoma crisis

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.

Excipient information

Dexamethasone 3.3 mg/ml solution for injection contains less than 1 mmol sodium (23 mg) per 2 ml of solution, that is to say essentially 'sodium-free'.

Dexamethasone formulations containing sulfites should not be used for intrathecal therapy. This sulfite-containing formulation has an altered risk profile compared to other sulfite-free formulations; there is a potential risk of neurotoxicity when administered intrathecally.

The excipient sodium sulfite may rarely cause severe hypersensitivity reactions and bronchospasm.

The vial stopper contains dry natural rubber (a derivative of latex), which may cause severe allergic reactions.

Paediatric population

Hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy was reported after systemic administration of corticosteroids including dexamethasone to prematurely born infants, therefore appropriate diagnostic evaluation and monitoring of cardiac function and structure should be performed. In the majority of cases reported, this was reversible on withdrawal of treatment. In preterm infants treated with systemic dexamethasone diagnostic evaluation and monitoring of cardiac function and structure should be performed (see section 4.8).

4.5 Interaction with other medicinal products and other forms of interaction

Liver enzyme inducing drugs such as barbiturates, ephedrine, rifampicin, rifabutin, carbamazepine, phenylbutazone, phenobarbital, phenytoin, primidone and aminoglutethimide may enhance the metabolism of corticosteroids, resulting in a decrease in pharmacological action, and a need for dosage adjustment.

The effects of anticholinesterases are antagonized by corticosteroids in myasthenia gravis.

The efficacy of coumarin anticoagulants may be enhanced by concurrent corticosteroid therapy and close monitoring of prothombin time or INR is required to avoid spontaneous bleeding. Corticosteroids may affect glucose tolerance and increase the dosage requirement for hypoglycaemic drugs (including insulin).

The incidence of gastro-intestinal ulceration is increased in patients receiving concomitant non-steroidal anti-inflammatory drugs and corticosteroids.

The renal clearance of salicylates is increased by corticosteroids and steroid withdrawal may result in salicylate intoxication. There may be interaction with salicylates in patients with hypoprothrombinemia.

Diuretics, hypoglycemic agents (including insulin), and cardiac glycosides are antagonised by corticosteroids and the hypokalaemic effects of acetazolamide, loop diuretics, thiazide diuretics and carbenoxolone are enhanced. Patients receiving corticosteroids and potassium depleting diuretics and/or cardiac glycosides, should be monitored for hypokalaemia. This is of particular importance in patients receiving cardiac glycosides, since hypokalaemia increases the toxicity of these drugs. The effects of anti-hypertensive drugs are also antagonised by corticosteroids.

Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid effects.

4.6 Fertility, pregnancy and lactation


The ability of corticosteroids to cross the placenta varies between individual drugs, however, dexamethasone readily crosses the placenta. Studies have shown an increased risk of neonatal hypoglycaemia following antenatal administration of a short course of corticosteroids including dexamethasone to women at risk for late preterm delivery.

Administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate, intra-uterine growth retardation and effects on brain growth and development. There is no evidence that corticosteroids result in an increased incidence of congenital abnormalities, such as cleft palate/lip in man. See also section 5.3 of the SmPC. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intra-uterine growth retardation. Hypoadrenalism may, in theory, occur in the neonate following prenatal exposure to the corticosteroids but usually resolves spontaneously following birth and is rarely clinically important. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks. When corticosteroids are essential however, patients with normal pregnancies may be treated as though they were in the non-gravid state.

There is evidence of harmful effects on pregnancy in animals. Infants born to mothers who have received substantial doses of corticosteroids during the pregnancy should be carefully observed, for signs of adrenal insufficiency.

Patients with pre-eclampsia or fluid retention require close monitoring.


Corticosteroids may pass into breast milk, although no data are available for dexamethasone. Infants of mothers taking high doses of systemic corticosteroids for prolonged periods may have a degree of adrenal suppression. Suppression of growth or other adverse effects may occur.

4.7 Effects on ability to drive and use machines

Not applicable.

4.8 Undesirable effects

Adverse Reactions

Reactions are common and may occur in both adults and children. In adults the frequency of severe reactions has been estimated to be 5-6%. Psychological effects have been reported on withdrawal of corticosteroids; the frequency is unknown.

The incidence of predictable undesirable effects, including hypothalamic-pituitary-adrenal suppression correlates with the relative potency of the drug, dosage, timing of administration and the duration of treatment (see section 4.4).

High doses of dexamethasone sodium phosphate are intended for short term therapy and therefore adverse reactions are uncommon. However, peptic ulceration and bronchospasm may occur.

Except for hypersensitivity, the following adverse effects have been associated with prolonged systemic corticosteroid therapy.

Endocrine disorders:

Suppression of the hypothalamic-pituitary adrenal axis; Cushing-like syndrome, secondary adrenocortical unresponsiveness, particularly in times of stress, as in surgery or trauma.

Metabolism and nutrition disorders:

Electrolyte imbalance (retention of sodium and water with oedema and hypertension); nitrogen depletion; hyperglycaemia; hypokalemic alkalosis; increased calcium and potassium excretion, weight gain, impaired glucose tolerance with increased requirement for anti-diabetic therapy; hyperglycaemia; negative protein/nitrogen and calcium balance; increased appetite.

Infections and Infestations:

Increased susceptibility to and severity of infection with suppression of clinical symptoms and signs; opportunistic infections; candidiasis, recurrence of dormant tuberculosis. (See section 4.4).

Musculoskeletal and connective tissue disorders:

Charcot-like arthropathy following intra-articular injection, Muscular atrophy, proximal myopathy, premature epiphyseal closure, osteoporosis, avascular osteonecrosis, muscle weakness, vertebral compression, suppression of growth in infancy, childhood and adolescence.

Gastro-intestinal disorders:

Dyspepsia, peptic ulceration with perforation and haemorrhage, oesophageal ulcerations, and acute pancreatitis.

Skin and subcutaneous disorders:

Skin atrophy - subcutaneous and cutaneous atrophy; telangiectasia and striae; petechiae and ecchymoses; erythema; increased sweating; possible suppression of skin tests; allergic dermatitis; urticaria, sterile abscess; hyperpigmentation; hypopigmentation; acne and hirsutism.

Nervous system disorders:

Headache; convulsions; burning or tingling; aggravation of epilepsy; increased intra-cranial pressure with papilloedema in children (pseudotumour cerebri), usually after treatment withdrawal; cognitive dysfunction; amnesia.

Ear and labyrinth disorders :


Psychiatric disorders

Affective disorders (such as irritable, euphoric, depressed and labile mood, and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations, and aggravation of schizophrenia), behavioural disturbances, irritability, anxiety, sleep disturbances, confusion, psychological dependence, aggravation of schizophrenia, mental disturbances, euphoria, depression, insomnia.

Eye disorders:

Posterior sub-capsular cataracts or increased intraocular pressure may result in glaucoma or occasionally damage to the optic nerve; exophthalmos papilloedema; corneal or scleral thinning; exacerbation of ophthalmic viral or fungal diseases. Blindness associated with intralesional therapy around the face and neck. Chorioretinopathy, blurred vision though the frequency is unknown (see also section 4.4).

Reproductive system and breast disorders

A transient burning or tingling sensation mainly in the perineal area following intravenous injection of large doses of corticosteroid phosphates, menstrual irregularities and amenorrhoea.

Blood and lymphatic system disorders

Diminished lymphoid tissue and leucocytosis

Injury, poisoning, and procedural complications

Bruising, tendon rupture and long bone fractures.

Vascular disorders

Thromboembolism and hypertension.

Immune system disorders

Diminished immune response, decreased responsiveness to vaccination. Hypersensitivity including anaphylaxis, has been reported.

Cardiac disorders:

Hypertrophic cardiomyopathy in prematurely born infants (see section 4.4).

General disorders and administration site conditions:

Post injection flare.


In patients who have received more than physiological doses of systemic corticosteroids (approximately 1 mg dexamethasone) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced. Clinical assessment of disease activity may be needed during withdrawal. If the disease is unlikely to relapse on withdrawal of systemic corticosteroids but there is uncertainty about HPA suppression, the dose of systemic corticosteroid may be reduced rapidly to physiological doses. Once a daily dose of 1 mg dexamethasone is reached, dose reduction should be slower to allow the HPA-axis to recover.

Abrupt withdrawal of systemic corticosteroid treatment, which has continued up to 3 weeks is appropriate if it is considered that the disease is unlikely to relapse. Abrupt withdrawal of doses up to 6 mg of dexamethasone for 3 weeks is unlikely to lead to clinically relevant HPA-axis suppression, in the majority of patients. In the following patient groups, gradual withdrawal of systemic corticosteroid therapy should be considered even after courses lasting 3 weeks or less:

• Patients who have had repeated courses of systemic corticosteroids, particularly if taken for greater than 3 weeks,

• When a short course has been prescribed within one year of cessation of long-term therapy (months or years),

• Patients who may have reasons for adrenocortical insufficiency other than exogenous corticosteroid therapy,

• Patients receiving doses of systemic corticosteroid greater than 6 mg daily of dexamethasone,

• Patients repeatedly taking doses in the evening.

Withdrawal symptoms and signs: Too rapid a reduction of corticosteroid dosage following prolonged treatment can lead to acute adrenal insufficiency, hypotension and death. (See section 4.4).

A 'withdrawal syndrome' may also occur including fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules and loss of weight.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

It is difficult to define an excessive dose of a corticosteroid as the therapeutic dose will vary according to the indication and patient requirements. High-dose corticosteroids given as recommended for pulse therapy are relatively free from hazardous effects.

Exaggeration of corticosteroid related adverse effects may occur. Treatment should be asymptomatic and supportive as necessary.

Treat anaphylaxis with adrenaline and positive pressure ventilation. Other supportive measures aimed to maintain the patient unstressed.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacology of the corticosteroids is complex and the drugs affect almost all body systems. Maximum pharmacological activity lags behind peak blood concentrations, suggesting that most effects of the drugs result from modification of enzyme activity rather than from direct actions by the drugs.

5.2 Pharmacokinetic properties

Intramuscular injections of dexamethasone phosphate give maximum plasma concentrations of dexamethasone at 1 hour. Dexamethasone is readily absorbed from the gastro-intestinal tract. Its biological half-life in plasma is about 190 minutes. Binding of dexamethasone to plasma proteins is less than for most other corticosteroids. Dexamethasone penetrates into tissue fluids and cerebrospinal fluids. Metabolism of the drug takes place in the kidneys and liver and excretion is via the urine.

5.3 Preclinical safety data

In animal studies, cleft palate was observed in rats, mice, hamsters, rabbits, dogs and primates; not in horses and sheep. In some cases these divergences were combined with defects of the central nervous system and of the heart. In primates, effects in the brain were seen after exposure. Moreover, intra-uterine growth can be delayed. All these effects were seen at high dosages.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium citrate, disodium edetate, sodium sulfite (E221), Water for Injections, sodium hydroxide and hydrochloric acid.

6.2 Incompatibilities

Dexamethasone sodium phosphate is physically incompatible with daunorubicin, doxorubicin and vancomycin and should not be admixed with solutions containing these drugs. Also incompatible with doxapram HCl and glycopyrrolate in syringe.

6.3 Shelf life

The shelf life of the product as packaged for sale is 24 months.

The product should be used immediately after first opening of the container.

The shelf life after dilution is 24 hours (see section 6.4)

6.4 Special precautions for storage

Do not store above 25° C. Do not freeze. Keep container in the outer carton.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8° C, unless dilution has taken place in controlled and validated aseptic conditions.

6.5 Nature and contents of container

2 ml Type I amber glass vial with 13 mm chlorobutyl-based rubber stopper and spun on aluminium cap. Cartons of 5 vials.

6.6 Special precautions for disposal and other handling

When dexamethasone sodium phosphate is given by intravenous infusion, only Sodium Chloride Injection BP or Glucose Injection BP should be used as diluents. The exact concentration of dexamethasone per infusion container should be determined by the desired dose, patient fluid intake and drip rate required.

For single use only. The product should only be used when the solution is clear and particle free. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Hospira UK Limited

Walton Oaks


Dorking Road



KT20 7NS


8. Marketing authorisation number(s)

PL 04515/0020

9. Date of first authorisation/renewal of the authorisation

15 February 1988/24 May 2000

10. Date of revision of the text


Ref: gxDM 11_1

Hospira UK Ltd
Company image
Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, UK
Medical Information Direct Line
+44 (0)1304 616161
Medical Information Fax
+44 (0)1304 656221